Goodwin Advises Repligen Corporation on the Acquisition of BioLife Solutions

The Life Sciences Public M&A team advised Repligen Corporation (NASDAQ: RGEN, “Repligen”) on the acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. In connection with the transaction, BioLife stockholders received approximately $31.00 per share in cash and Repligen stock. As a combined commercial team, BioLife will benefit from Repligen’s broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships.

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. They are “inspiring advances in bioprocessing” for the customers they serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Repligen’s focus areas are Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins.

The Goodwin team was led by led by Stuart Cable, Jacqueline Mercier, and Tevia Pollard, and included Kathryn Clerici, Andrea Akinbola, Keerthi Adusumilli, Bonnee Nie, Hugh Rennie, Haley Carter, Artimus Cunningham, Jeffrey Toomey, John Vernaglia, Julie Tibbets, Elizabeth Mulkey, Matthew Wetzel, Alexandra Denniston, Rahat Tariq, Timothy Holahan, Ana Victoria Alvarado, Daniel Karelitz, Chase Gorland, Scott Bluni, Catherine McCarty, Omer Tene, Justin Pierce, Kuwabo O’Brien, Mark Tully, Amanda Russo, Adam Bellack, Brian Mukherjee, Amy Koss, Arman Oruc, Paul Jin, Kevin Walsh, Michael Casaburi, Deborah Birnbach, Richie Schwartz, and Jessica Park.

For more information on the deal, please read the press release.